Haibang Capital logo

Haibang Capital

Asia, Zhejiang, China, Hangzhou

Description

Haibang Capital is an investment company focusing on venture capital and private equity.

Investor Profile

Haibang Capital has made 4 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Series B (75%)
  • Series D (25%)

Country Focus

  • China (100%)

Industry Focus

  • Biotechnology
  • Pharmaceutical
  • Biopharma
  • Health Care
  • Manufacturing
  • Medical
  • Medical Device
  • Therapeutics
  • Commercial
  • Energy
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Haibang Capital frequently co-invest with?

Co-Investments: 1
GT
Asia, Fujian, China, Jiangxi
Co-Investments: 1
Conswall Capital
Asia, Shanghai, China, Shanghai
Co-Investments: 1
HK
Asia, Shanghai, China, Shanghai
Co-Investments: 1
Dongfang Jiafu
Asia, Zhejiang, China, Hangzhou
Co-Investments: 1
BM
North America, California, United States, Dublin
Co-Investments: 1
Yinxinggu Capital
Asia, Zhejiang, China, Hangzhou
Co-Investments: 1
Co-Investments: 1
HT Capital
Asia, Shanghai, China, Shanghai
Co-Investments: 1
Haitong Capital
Europe, Lisboa, Portugal, Lisbon
Co-Investments: 1

What are some of recent deals done by Haibang Capital?

Microquanta

Hangzhou, Zhejiang, China

Microquanta is a Hangzhou-based maker of perovskite solar cell, which is a new form of solar technology.

CommercialEnergySolar
Series DOct 9, 2022
Healsun Biopharm

Hangzhou, Zhejiang, China

Healsun Biopharm is a Biopharmaceutical company that focuses on antibody/recombinant protein CRO/CDMO

BiopharmaBiotechnologyHealth CarePharmaceutical
Series BAug 19, 2022
Amount Raised: $36,672,485
DECANS

Jiaxing, Zhejiang, China

DECANS manufactures orthopedic implants and surgical technology systems.

ManufacturingMedicalMedical Device
Series BFeb 21, 2022
Amount Raised: $78,922,861
IMPACT Therapeutics

Nanjing, Jiangsu, China

IMPACT Therapeutics is a therapeutics company dedicated to the development of similar drugs to treat cancer.

BiotechnologyPharmaceuticalTherapeutics
Series BFeb 22, 2016
Amount Raised: $10,000,000